Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Management of Indolent Non-Hodgkin Lymphomas
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for the Treatment of Metastatic Breast Cancer
Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia
It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
New Treatment Options and Toxicity Management in Acute Lymphoblastic Leukemia
Newer agents used in the treatment of acute lymphoblastic leukemia (ALL) have led to improved clinical outcomes, but are associated with significant toxicities. Clinicians need to be educated on appropriate management approaches for the side effects associated with these new therapies to allow patients to receive maximal benefit and optimal care.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Treating Acute Myeloid Leukemia in 2022: Evolving Concepts and Management Strategies
To help patients have the best outcomes possible, clinicians need education on selection of therapy (high-intensity, low-intensity, or targeted) and on how best to manage toxicities and provide supportive care.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of Systemic Amyloidosis
Physician suspicion and awareness to the possibility of amyloidosis is a critical first step in diagnosing systemic light-chain amyloidosis (SLCA). To optimize patient care, clinicians need education about the evolving options for managing patients with SLCA.
Category
  • Systemic Light Chain Amyloidosis
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Treatment Decisions in Multiple Myeloma
Clinicians must understand the treatment evolution and guidelines for when to administer two-, three-, or four drug regimens as initial or subsequent therapy in context of the patient's therapeutic and disease history. In addition, it is important for clinicians to educate patients about their different treatment options (e.g., administration and adverse events) and discuss patient preferences and individual circumstances that may affect treatment recommendations.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
How to Incorporate Immunotherapies in the Management of Multiple Myeloma
Education about individualizing treatment strategies will assist healthcare providers to make informed decisions about incorporating immunotherapies into treatment regimens. 
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Pages